Submit Content
Get the latest delivered to your inbox
Privacy Policy

Alnylam Pharmaceuticals

About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science, and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.

    Alnylam Issues 2022 Corporate Responsibility Report Image

    POSTED 

    05-03-23

    Alnylam Issues 2022 Corporate Responsibility Report

    Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today published its 2022 Corporate Responsibility Report. This year’s edition reasserts our commitment to advancing pioneering RNAi science and supporting health equity.
    Alnylam Issues 2021 Corporate Responsibility Report Image

    POSTED 

    03-16-22

    Alnylam Issues 2021 Corporate Responsibility Report

    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published its 2021 Corporate Responsibility Report.
    Alnylam Pharmaceuticals

    Alnylam Pharmaceuticals

    Alnylam Pharmaceuticals

    Join today and get the latest delivered to your inbox